secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001104659-25-099356
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio raises ~$6M in registered direct offering of 4M shares/pre-funded warrants at $1.50/share
--------------------------------------------------------------------------------

- Offering comprises 3.15M shares and 850K pre-funded warrants at $1.50 per share (warrant price $1.4999); gross proceeds ~$6M.
- Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease, working capital, and general corporate purposes.
- H.C. Wainwright acts as exclusive placement agent; 7% cash fee plus 200K warrants exercisable at $2.20 per share for 5 years.
- Officers and directors subject to 45-day lock-up from closing date, which is expected on or about October 13-14, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925099356/0001104659-25-099356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925099356/tm2528502d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-099356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer